https://www.selleckchem.com/products/ag-270.html
Scalp psoriasis is common and is often severe enough to negatively impact quality of life (QOL).1,2 In STYLE (NCT03123471), oral apremilast 30 mg twice daily (BID) demonstrated significantly greater improvements in moderate to severe plaque psoriasis of the scalp, scalp itch, whole body itch, and QOL versus placebo3 during the 16-week, placebo-controlled phase; safety and tolerability were consistent with the known safety profile of apremilast.3,4 We report the efficacy and safety of apremilast during the apremilast extension phase of ST
Aimer
Commentaire
Partagez
